A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy.

Autor: Federman N; Department of Pediatrics, Mattel Children's Hospital, University of California.; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA.; Department of Orthopaedics, UCLA David Geffen School of Medicine, Frazer, PA., Dragomir MD; Oncological Institute 'Prof. Dr. Al. Trestioreanu', Bucharest, Romania., Kizyma Z; Western Ukrainian Specialized Pediatric Medical Centre, Lviv, Ukraine., Roganovic J; Clinical Hospital Center Rijeka, Rijeka, Croatia., Bias P; Teva ratiopharm, Merckle GmbH, Ulm, Germany., Lammerich A; Teva ratiopharm, Merckle GmbH, Ulm, Germany., Ben Arie ZR; Teva Pharmaceuticals Industries Ltd, Petach Tikva, Israel., Zou L; Biologics, Assays and Technology, Teva Pharmaceuticals Inc., West Chester., Hoehn G; Teva Pharmaceuticals, North American Medical Affairs, Frazer, PA., Buchner A; Teva ratiopharm, Merckle GmbH, Ulm, Germany.

Publikováno v: Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2019 Oct; Vol. 41 (7), pp. 525-531.